Harrow, Inc.
$40.5
▼
-0.34%
2026-04-21 07:21:00
www.harrow.com
NGM: HROW
Explore Harrow, Inc. stock price, valuation, financial statements, dividend history, analyst estimates, and long-term business fundamentals on StockSifting.
Market Cap
$1.51 B
Current Price
$40.5
52W High / Low
$54.85 / $21.12
Stock P/E
—
Book Value
$1.41
Dividend Yield
—
ROCE
10.06%
ROE
-8.47%
Face Value
—
EPS
$-0.14
Exp Qtr EPS
—
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Employees
373
Beta
0.31
Debt / Equity
483.72
Current Ratio
2.2
Quick Ratio
2.06
Forward P/E
13.21
Price / Sales
4.91
Enterprise Value
$1.51 B
EV / EBITDA
31.02
EV / Revenue
5.56
Rating
Strong Buy
Target Price
$68.25
EPS Forecast (FY)
—
Pros
- Short-term liquidity looks comfortable.
- Strong operating margin profile.
- Valuation is not stretched on P/E basis.
Cons
- Return on equity is on the weaker side.
- Leverage is relatively high.
- Net margin is relatively low.
Sift Stocks
| S.No. | Name | Price | P.E. | Market Cap | Div Yld % | ROCE | ROE | 52Week High/ Low | Book Value |
|---|---|---|---|---|---|---|---|---|---|
| 1. | Citius Oncology, Inc. | $0.92 | — | $77.5 M | — | -45.72% | -47.41% | $6.19 / $0.49 | $0.69 |
| 2. | SCYNEXIS, Inc. | $1.07 | — | $47.85 M | — | -30.16% | -16.48% | $1.31 / $0.56 | $1.13 |
| 3. | Sunshine Biopharma, Inc. | $1.02 | — | $5.05 M | — | -23.97% | -25.68% | $2.43 / $0.95 | $5.31 |
| 4. | Ironwood Pharmaceuticals, Inc. | $4.42 | 29.94 | $719.09 M | — | 76.78% | -8.53% | $5.78 / $0.53 | $-1.61 |
| 5. | InterCure Ltd. | $0.75 | — | $125.93 M | — | -8.41% | -16.68% | $605 / $225.3 | $7.59 |
| 6. | Aytu BioPharma, Inc. | $2.58 | — | $27.69 M | — | 4.15% | -1.09% | $3.06 / $0.98 | $1.32 |
| 7. | Supernus Pharmaceuticals, Inc. | $51.25 | — | $2.92 B | — | -3.31% | -3.68% | $59.68 / $29.16 | $18.48 |
Quarterly Results
Figures shown in M / B
| Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | |
|---|---|---|---|---|---|---|
| Sales | 89.09 M | 71.64 M | 63.74 M | 47.83 M | 66.83 M | — |
| Operating Profit | 15.59 M | 14.75 M | 11.41 M | -11.23 M | 13.15 M | — |
| Net Profit | 6.63 M | 1.02 M | 5 M | -17.78 M | 6.78 M | — |
| EPS in Rs | 0.18 | 0.03 | 0.13 | -0.48 | 0.18 | -0.12 |
Profit & Loss
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Sales | 272.3 M | 199.61 M | 130.19 M | 88.59 M |
| Operating Profit | 30.52 M | 9.07 M | 0.81 M | 1.92 M |
| Net Profit | -5.14 M | -17.48 M | -24.41 M | -14.09 M |
| EPS in Rs | -0.14 | -0.47 | -0.66 | -0.38 |
Balance Sheet
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Total Assets | 399.48 M | 388.97 M | 312.16 M | 157.38 M |
| Total Liabilities | 347.39 M | 319.67 M | 241.75 M | 130.14 M |
| Equity | 52.45 M | 69.65 M | 70.77 M | 27.59 M |
| Current Assets | 211.75 M | 189.65 M | 139.48 M | 118.26 M |
| Current Liabilities | 96.3 M | 91.34 M | 49.34 M | 18.63 M |
Cash Flow
Last available yearly cash flow history
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Operating CF | 43.86 M | -22.2 M | 3.84 M | 1.71 M |
| Investing CF | -5.46 M | -33.16 M | -152.55 M | -1.74 M |
| Financing CF | -12.72 M | 28.53 M | 126.53 M | 54.14 M |
| Free CF | 42.76 M | -60.88 M | -148.71 M | -6.07 M |
| Capex | -1.1 M | -38.67 M | -152.55 M | -7.77 M |
5Y Margin & Growth History
Last 5 year derived history from yfinance annual statements
| 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|
| Revenue Growth % | 53.32% | 46.95% | — | — |
| Earnings Growth % | 28.39% | -73.3% | — | — |
| Profit Margin % | -8.76% | -18.75% | -15.9% | — |
| Operating Margin % | 4.55% | 0.62% | 2.17% | — |
| Gross Margin % | 75.33% | 69.55% | 71.35% | — |
| EBITDA Margin % | 10.02% | 7.65% | -3.5% | — |
Dividend & Split History
Latest dividend and stock split events stored from yfinance
Dividend History
No dividend history available.
Stock Splits
No stock split history available.